摘要
目的研究紫杉醇加顺铂方案(TP)新辅助化疗联合放疗治疗晚期鼻咽癌的临床疗效。方法1998年1月至2001年1月57例病理确诊为鼻咽癌,根据福州1992年分期标准,57例均为Ⅲ、Ⅳa期的初治患者,随机分为综合组27例,单放组30例。综合组行TP方案新辅助化疗2个疗程后放疗。结果综合组与单放组鼻咽全消率分别为96.3%和83.0%(P<0.05),颈部淋巴结全消率分别为100%和93.3%(P>0.05)。综合组胃肠道反应、口腔黏膜反应、皮肤反应及白细胞减少等毒副反应均强于单放组,但差异无显著性(P>0.05)。综合组5年生存率(59.3%)与单放组(43.3%)相比差异无显著性(P>0.05)。结论TP方案新辅助化疗联合放疗可提高肿瘤局控率,未能提高晚期鼻咽癌生存率。
Objective To evaluate the efficacy of chemotherapy combined with radiotherapy in treatment of the patients with advanced nasopharyngeal carcinoma （NPC）. Methods From Jan. 1998 to Jan. 2001,27 patients with stages Ⅲ and Ⅳa NPC（92 stage system ） received two courses of PT（ paclitaxel and eisplatin） protocol chemotherapy before radiotherapy and 30 patients received radiotherapy alone. Resuits The overall response rates of adjuvant chemotherapy with radiotherapy （CT/RT） group and radiotherapy （RT） group were 96. 2% and 83.0% （P 〈0. 05） for local nasopharyngeal disease, and 100% and 93.9% （P 〉 0.05） for cervical lymph node respectively. There were no significant differences in the incidence and severity of gastrointestinal side reaction, oral mucositis, dermatitis and bone marrow depression between the two groups. The 5-year survival rate was 59. 3% in CT/RT group and 43.3% in RT group （P 〉 0. 05）. Conclusion PT protocol of adjuvant chemotherapy combined with radiotherapy in treatment of advanced NPC can improve the local control rate of NPC, but has no benefit to the survival rate.
出处
《中国肿瘤临床与康复》
2008年第5期426-428,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
鼻咽肿瘤
紫杉醇
新辅助化疗
放射治疗
Nasopharyngeal neoplasms
Paclitaxel
Induction chemotherapy
Radiotherapy
